Entity Details

Primary name VGFR3_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionP35916
EntryNameVGFR3_HUMAN
FullNameVascular endothelial growth factor receptor 3
TaxID9606
Evidenceevidence at protein level
Length1363
SequenceStatuscomplete
DateCreated1994-06-01
DateModified2021-06-02

Ontological Relatives

GenesFLT4

GO terms

Show/Hide Table
GOName
GO:0001934 positive regulation of protein phosphorylation
GO:0001938 positive regulation of endothelial cell proliferation
GO:0001944 vasculature development
GO:0001945 lymph vessel development
GO:0001946 lymphangiogenesis
GO:0002040 sprouting angiogenesis
GO:0002244 hematopoietic progenitor cell differentiation
GO:0003016 respiratory system process
GO:0004714 transmembrane receptor protein tyrosine kinase activity
GO:0005021 vascular endothelial growth factor-activated receptor activity
GO:0005524 ATP binding
GO:0005576 extracellular region
GO:0005654 nucleoplasm
GO:0005829 cytosol
GO:0005886 plasma membrane
GO:0005887 integral component of plasma membrane
GO:0007169 transmembrane receptor protein tyrosine kinase signaling pathway
GO:0007275 multicellular organism development
GO:0008284 positive regulation of cell population proliferation
GO:0010575 positive regulation of vascular endothelial growth factor production
GO:0010595 positive regulation of endothelial cell migration
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0019838 growth factor binding
GO:0019903 protein phosphatase binding
GO:0033674 positive regulation of kinase activity
GO:0035924 cellular response to vascular endothelial growth factor stimulus
GO:0038084 vascular endothelial growth factor signaling pathway
GO:0042803 protein homodimerization activity
GO:0043066 negative regulation of apoptotic process
GO:0043235 receptor complex
GO:0043410 positive regulation of MAPK cascade
GO:0046330 positive regulation of JNK cascade
GO:0046777 protein autophosphorylation
GO:0048010 vascular endothelial growth factor receptor signaling pathway
GO:0048286 lung alveolus development
GO:0048514 blood vessel morphogenesis
GO:0060312 regulation of blood vessel remodeling
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0090037 positive regulation of protein kinase C signaling

Subcellular Location

Show/Hide Table
Subcellular Location
Cell membrane
Cytoplasm
Nucleus
Secreted

Domains

Show/Hide Table
DomainNameCategoryType
IPR000719 Protein kinase domainDomainDomain
IPR001245 Serine-threonine/tyrosine-protein kinase, catalytic domainDomainDomain
IPR001824 Tyrosine-protein kinase, receptor class III, conserved siteSiteConserved site
IPR003598 Immunoglobulin subtype 2DomainDomain
IPR003599 Immunoglobulin subtypeDomainDomain
IPR007110 Immunoglobulin-like domainDomainDomain
IPR008266 Tyrosine-protein kinase, active siteSiteActive site
IPR009137 Vascular endothelial growth factor receptor 3 (VEGFR3)FamilyFamily
IPR011009 Protein kinase-like domain superfamilyFamilyHomologous superfamily
IPR013098 Immunoglobulin I-setDomainDomain
IPR013783 Immunoglobulin-like foldFamilyHomologous superfamily
IPR017441 Protein kinase, ATP binding siteSiteBinding site
IPR020635 Tyrosine-protein kinase, catalytic domainDomainDomain
IPR036179 Immunoglobulin-like domain superfamilyFamilyHomologous superfamily
IPR041348 VEGFR-2, Transmembrane domainDomainDomain

Diseases

Show/Hide Table
Disease IDSourceNameDescription
618780 OMIMCongenital heart defects, multiple types, 7 (CHTD7)An autosomal dominant disorder with incomplete penetrance characterized by congenital developmental abnormalities involving structures of the heart. Common defects include tetralogy of Fallot, pulmonary stenosis or atresia, absent pulmonary valve, right aortic arch, double aortic arch, and major aortopulmonary collateral arteries. The disease is caused by variants affecting the gene represented in this entry.
153100 OMIMLymphatic malformation 1 (LMPHM1)A form of primary lymphedema, a disease characterized by swelling of body parts due to developmental anomalies and functional defects of the lymphatic system. Patients with lymphedema may suffer from recurrent local infections. LMPHM1 is an autosomal dominant form with variable expression and severity. Onset is usually at birth or in early childhood but can occur later. Affected individuals manifest lymphedema, predominantly in the lower limbs, and hypoplasia of lymphatic vessels. Additional features are hemangioma and nail dysplasia or papillomatosis. The disease is caused by variants affecting the gene represented in this entry.
602089 OMIMHemangioma, capillary infantile (HCI)A condition characterized by dull red, firm, dome-shaped hemangiomas, sharply demarcated from surrounding skin, usually presenting at birth or occurring within the first two or three months of life. They result from highly proliferative, localized growth of capillary endothelium and generally undergo regression and involution without scarring. Disease susceptibility is associated with variants affecting the gene represented in this entry.

Drugs

Show/Hide Table
DrugNameSourceType
DB00398 SorafenibDrugbanksmall molecule
DB01268 SunitinibDrugbanksmall molecule
DB04879 VatalanibDrugbanksmall molecule
DB05075 TG-100801Drugbanksmall molecule
DB05932 DenibulinDrugbanksmall molecule
DB06080 ABT-869Drugbanksmall molecule
DB06101 IMC-1C11Drugbankbiotech
DB06589 PazopanibDrugbanksmall molecule
DB06626 AxitinibDrugbanksmall molecule
DB08896 RegorafenibDrugbanksmall molecule
DB09078 LenvatinibDrugbanksmall molecule
DB09079 NintedanibDrugbanksmall molecule
DB12010 FostamatinibDrugbanksmall molecule
DB15685 SelpercatinibDrugbanksmall molecule